Tirzepatide Has Six Maintenance Doses: How to Pick Yours

One thing that surprises people switching from semaglutide to tirzepatide: the dosing ladder is longer. Semaglutide for weight loss tops out at 2.4 mg with four maintenance steps. Tirzepatide offers six distinct doses — 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly — and the difference isn't just a pharmaceutical footnote. It changes the clinical logic of finding your dose.

Understanding the tirzepatide maintenance dose framework — what each level does, who tends to stay at each one, and when it makes sense to push higher vs hold — is one of the most practical conversations you can have about this drug.

The Six Doses: What They Are and Why They Exist

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Unlike semaglutide, which works on a single receptor, tirzepatide activates two — the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both pathways have dose-response curves, and Eli Lilly's clinical development showed that more people found their "sweet spot" at different points on that curve than with single-agonist drugs.

The approved dose levels under Mounjaro (for type 2 diabetes) and Zepbound (for weight loss) are:

The 2.5 mg starting dose is a ramp — you stay there for 4 weeks and then move up. It is not typically a destination. Everything from 5 mg upward can function as maintenance depending on your goals and tolerability.

How the Titration Schedule Works

The standard titration moves up every 4 weeks, one level at a time:

• Weeks 1–4: 2.5 mg
• Weeks 5–8: 5 mg
• Weeks 9–12: 7.5 mg
• Weeks 13–16: 10 mg
• Weeks 17–20: 12.5 mg
• Weeks 21+: 15 mg

This is the approved default. In practice, many providers slow the schedule — staying at a level for 8 weeks instead of 4 if nausea, fatigue, or significant appetite suppression is present. You don't have to reach 15 mg if you're losing weight effectively at a lower dose. That point is often under-communicated.

The flip side is also true: some people tolerate tirzepatide unusually well and can ramp faster under medical supervision, though this should happen carefully given the risk of underestimating delayed side effects.

Factors That Influence Maintenance Dose Selection

Weight loss rate at each level

The most useful signal for whether to advance is your actual rate of progress, not just tolerability. The SURMOUNT-1 trial showed dose-dependent weight loss:

• 5 mg: ~15% body weight loss at 72 weeks
• 10 mg: ~19.5% at 72 weeks
• 15 mg: ~20.9% at 72 weeks

The marginal gain from 10 → 15 mg is real but smaller than the gain from 5 → 10 mg. If you're on 10 mg and losing 1+ lb/week consistently, your prescriber may reasonably suggest holding rather than advancing.

Tolerability signals that suggest holding

• Nausea lasting more than 3–4 days after each injection
• Reflux or heartburn that's disrupting sleep
• Vomiting (even once) in the week after a dose increase
• Appetite suppression so strong that eating adequate protein is difficult

Any of these suggests the current level is pharmacologically meaningful for you — your gut is responding. Going higher too quickly typically makes these worse without proportionally improving outcomes.

Diabetes management

For Mounjaro users with type 2 diabetes, A1c reduction plateaus at lower doses than weight loss does for many people. The SURPASS-2 trial showed that meaningful A1c reduction happens across all dose levels. Some endocrinologists choose to hold at 7.5 or 10 mg once glycemic targets are met, rather than advancing for weight loss alone.

Why Some People Stay at 5 mg

A meaningful minority of tirzepatide users find 5 mg is their maintenance dose. This tends to happen when:

• They lost 12–15% of body weight and are satisfied with results
• They have tolerability issues at 7.5 mg that don't resolve
• Their prescriber is managing a comorbidity (e.g., gallbladder disease) where higher dose risks outweigh benefits
• Supply constraints make a lower, more available dose the practical choice

Staying at 5 mg isn't failing — it's recognizing that the effective dose is the one your body responds to, not the highest available.

Dose Reductions Are an Option

Something that doesn't come up enough: you can step down to a lower dose if needed. Side effects that don't resolve after 8 weeks at a given level, significant muscle cramps, or persistent fatigue are all reasonable grounds to go back one level. This is particularly common in people who advance to 15 mg and find nausea or fatigue chronic rather than transient.

Stepping down doesn't reset your progress. The drug stays in your system (tirzepatide has a roughly 5-day half-life), and most people maintain their weight loss when reducing from 15 → 12.5 mg or 12.5 → 10 mg.

What to Discuss With Your Prescriber

At each dose level, the practical questions are:

1. Am I losing weight at a pace consistent with my goals?
2. Are my side effects tolerable enough that I could sustain this dose long-term?
3. If I'm not losing weight: is it dose, adherence, or a plateau that needs a non-dose intervention?

The sixth dose gives tirzepatide a flexibility that's clinically useful — but only if you're thinking about it as a range to find your window, not a ladder you have to climb to the top.

Related reading

• Tirzepatide: the complete guide
• Semaglutide dosing schedule
• GLP-1 weight loss timelines
• Reconstitution calculator